Ocular infections:

Indications for: BESIVANCE

Susceptible bacterial conjunctivitis.

Clinical Trials:

In a randomized, double-masked, vehicle-controlled, multicenter clinical trial, in which patients 1-98 years of age were dosed 3 times a day for 5 days, Besivance was superior to vehicle in patients with bacterial conjunctivitis. 

Clinical resolution was achieved in 45% (n=90/198) for the Besivance-treated group vs 33% (n=63/191) for the vehicle-treated group (difference 12%; 95% CI, 3-22). 

Microbiological outcomes demonstrated a statistically significant eradication rate for causative pathogens of 91% (n=181/198) for the Besivance-treated group vs 60% (n=114/191) for the vehicle-treated group (difference 31%; 95% CI, 23-40). 

Microbiologic eradication does not always correlate with clinical outcome in anti-infective trials.

Adults and Children:

<1yr: not established. ≥1yr: 1 drop in affected eye(s) 3 times daily (4–12hrs apart) for 7 days. Shake bottle once before use.

BESIVANCE Warnings/Precautions:

Not for inj into the eye. Avoid contact lenses during therapy or if symptomatic.  Prolonged use may result in overgrowth of nonsusceptible organisms. Pregnancy. Nursing mothers.

BESIVANCE Classification:


Adverse Reactions:

Conjunctival redness, blurred vision, eye pain/pruritus/irritation, headache; superinfection (discontinue and treat).

Drug Elimination:

The average elimination half-life of besifloxacin in plasma following multiple dosing was estimated to be 7 hours.

How Supplied: